Determination of BPI15086 and Its Metabolite in Human Plasma By Ultra-High Performance Liquid Chromatography–MS/MS and Its Application to a Pharmacokinetic Study

Reference

• Fitzmaurice C , DickerD, PainAet al. The global burden of cancer 2013. JAMA Oncol.1(4), 505–527 (2015).
   PubMed Web of Science ®Google Scholar
• Gridelli C , RossiA, CarboneDPet al. Non-small-cell lung cancer. Nat. Rev. Dis. Primers1, 15009 (2015).
   PubMed Web of Science ®Google Scholar
• Burstein HJ , SchwartzRS. Molecular origins of cancer. N. Enql. J. Med.358(5), 527 (2008).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD, JemalA. Cancer statistics. CA Cancer J. Clin.67(1), 7–30 (2017).
   PubMed Web of Science ®Google Scholar
• Costa DB , KobayashiSS. Whacking a molecule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl. Lung Cancer Res.4(6), 809–815 (2015).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, ThonqprasertSet al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou C , WuYL, ChenGet al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase III study. Lancet Oncol.12(8), 735–742 (2001).
   Google Scholar
• Rosell R , CarcerenyE, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Maemondo M , InoueA, KobayashiKet al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Sequist LV , YangJC, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.31(27), 3327–3334 (2013).
   PubMed Web of Science ®Google Scholar
• Yu HA , ArcilaME, RekhtmanNet al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res.19(8), 2240–2247 (2013).
   PubMed Web of Science ®Google Scholar
• Li D , AmbroqioL, ShimamuraTet al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene27(34), 4702–4711 (2008).
   PubMed Web of Science ®Google Scholar
• Engelman JA , ZejnullahuK, GaleCMet al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res.67(24), 11924–11932 (2007).
   PubMed Web of Science ®Google Scholar
• Ramalinqam SS , BlackhallF, KrzakowskiMet al. Randomized Phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. Clin. Oncol.30(27), 3337–3344 (2012).
   Web of Science ®Google Scholar
• Miller VA , HirshV, CadranelJet al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase IIb/III randomised trial. Lancet Oncol.13(5), 528–538 (2012).
   PubMed Web of Science ®Google Scholar
• Katakami N , AtaqiS, GotoKet al. LUX-lung 4: a Phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol.31(27), 3335–3342 (2013).
   PubMed Web of Science ®Google Scholar
• Nquyen KS , NwalJW, WakeleeH. Review of the current targeted therapies for non-small-cell lung cancer. World J. Clin. Oncol.5(4), 576–87 (2014).
   PubMedGoogle Scholar
• Attwa MW , KadiAA, AbdelhameedAS. Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: In vitro metabolic investigation. J. Pharm. Biomed. Anal.5(164), 659–667 (2019).
   Google Scholar
• Platform for Registry and Publicity of Drug Clinical Trials, Chinese clinical trial website. Registration No. CTR20160704. http://www.chinadrugtrials.org.cn
   Google Scholar
• ClinicalTrial.gov, American clinical trial website. https://clinicaltrials.gov/ct2/show/NCT02914990?term=BPI15086&rank=1
   Google Scholar
• Wani TA . Highly sensitive ultra-performance liquid chromatography–tandem mass spectrometry method for the determination of abiraterone in human plasma. Anal. Methods5(15), 3693–3699 (2013).
   Web of Science ®Google Scholar
• Iqbal M , WaniTA, KhalilNYet al. Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. Chem. Cent. J.7(1), 7 (2013).
   PubMedGoogle Scholar
• Kadi AA , AbdelhameedAS, DarwishHWet al. A highly efficient and sensitive LC–MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study. Biomed. Chromatogr.30(8), 1248–1255 (2016).
   PubMed Web of Science ®Google Scholar
• US FDA. Guidance for Industry: bioanalytical method validation (2013). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf
   Google Scholar
• European Medicines Agency (EMA). Guideline Bioanalytical Method Validation (2012). http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2011/08/WC500109686.pdf
   Google Scholar
• China Food and Drug Administration (CFDA). Guideline on Bioanalytical Method Validation, China Pharmacopeia (version 2015). Part 2, 363–368 (2015). https://wenku.baidu.com/view/72cbb849ce2f0066f433225f.html
   Google Scholar
• Matuszewski BK , ConstanzerML, Chavez-EnqCM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem.70(5), 882–889 (1998).
   PubMed Web of Science ®Google Scholar
• Chavez-Enq CM , ConstanzerML, MatuszewskiBK. Simultaneous determination of aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. J. Pharm. Biomed. Anal.35(5), 1213–1229 (2004).
   PubMed Web of Science ®Google Scholar
• Yadav M , ShrivastavPS. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research. Bioanalysis3(9), 1007–1024 (2011).
   PubMed Web of Science ®Google Scholar